Greatly increased numbers of histamine cells in human narcolepsy with cataplexy

Annals of Neurology

Volumn 74, Issue 6, 2013, Pages 786-793

  John, Joshi ^a   Thannickal, Thomas C ^a   McGregor, Ronald ^a   Ramanathan, Lalini ^a   Ohtsu, Hiroshi ^b   Nishino, Seiji ^c   Sakai, Noriaki ^c   Yamanaka, Akhiro ^d   Stone, Carly ^a   Cornford, Marcia ^e   Siegel, Jerome M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TOHOKU UNIVERSITY   (Japan)

^c STANFORD UNIVERSITY   (United States)

^d NAGOYA UNIVERSITY   (Japan)

^e HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ATAXIN 3; DIPHTHERIA TOXIN; DOXYCYCLINE; HISTAMINE; HISTIDINE DECARBOXYLASE; OREXIN 2 RECEPTOR; PEPTIDE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CATAPLEXY; CELL COUNT; CELL DESTRUCTION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG USE; FEMALE; HISTAMINE CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MALE; MICROSCOPY; MIDDLE AGED; MONOAMINE NERVE CELL; MOUSE; MUTANT DOG; NARCOLEPSY; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE; VERY ELDERLY;

ADULT; AGED, 80 AND OVER; ANIMALS; BRAIN; CATAPLEXY; CELL COUNT; DISEASE MODELS, ANIMAL; DOGS; FEMALE; HISTAMINE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MIDDLE AGED; MUTATION; NARCOLEPSY; NEURONS;

EID: 84892912382     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23968     Document Type: Article

References (48)

1. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469-474.
2. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991-997.
3. Thannickal TC, Nienhuis R, Siegel JM,. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep 2009; 32: 993-998.
4. Guilleminault C, Cao MT,. Narcolepsy: diagnosis and management. In:, Kryger MH, Roth T, Dement WC, eds. Principles and practice of sleep medicine. 5th ed. St Louis, MO: Elsevier Saunders, 2011: 957-968.
5. Lin L, Faraco J, Kadotani H, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor gene. Cell 1999; 98: 365-376.
6. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98: 437-451.
7. Blouin AM, Thannickal TC, Worley PF, et al. Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. Neurology 2005; 65: 1189-1192.
8. Crocker A, Espana RA, Papadopoulou M, et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005; 65: 1184-1188.
9. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001; 30: 345-354.
10. Nishino S, Okura M, Mignot E,. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med Rev 2000; 4: 57-99.
11. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998; 18: 9996-10015.
12. Haas HL, Sergeeva OA, Selbach O,. Histamine in the nervous system. Physiol Rev 2008; 88: 1183-1241.
13. Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis 2008; 30: 74-83.
14. Huang ZL, Qu WM, Li WD, et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci U S A 2001; 98: 9965-9970.
15. John J, Wu M-F, Boehmer LN, et al. Cataplexy-active neurons in the posterior hypothalamus: implications for the role of histamine in sleep and waking behavior. Neuron 2004; 42: 619-634.
16. Howard CV, Reed MG,. Unbiased stereology: three dimensional measurement in microscopy. New York, NY: Springer-Verlag, 1998.
17. Ohtsu H,. Histamine synthesis and lessons learned from histidine decarboxylase deficient mice. Adv Exp Med Biol 2010; 709: 21-31.
18. Inutsuka S, Tabuchi S, Tsunematsu T, et al. New model mice for narcolepsy using timing controlled gene expression in transgenic mice which induces specific ablation of orexin/hypocretin neurons. Soc Neurosci 2012; 799: 19.
19. Inagaki N, Yamatodani A, Shinoda K, et al. Histaminergic nerve fibers in the median eminence and hypophysis of rats demonstrated immunocytochemically with antibodies against histidine decarboxylase and histamine. Brain Res 1988; 439: 402-405.
20. Anichtchik OV, Rinne JO, Kalimo H, et al. An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Exp Neurol 2000; 163: 20-30.
21. Airaksinen MS, Paetau A, Paljarvi L, et al. Histamine neurons in human hypothalamus: anatomy in normal and Alzheimer diseased brains. Neuroscience 1991; 44: 465-481.
22. Bassetti CL, Baumann CR, Dauvilliers Y, et al. Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin. J Sleep Res 2010; 19: 620-623.
23. Nishino S, Sakurai E, Nevsimalova S, et al. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Sleep 2009; 32: 175-180.
24. Dauvilliers Y, Delallee N, Jaussent I, et al. Normal cerebrospinal fluid histamine and tele-methylhistamine levels in hypersomnia conditions. Sleep 2012; 35: 1359-1366.
25. Nishino S, Fujiki N, Ripley B, et al. Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci Lett 2001; 313: 125-128.
26. van Wamelen DJ, Shan L, Aziz NA, et al. Functional increase of brain histaminergic signaling in Huntington's disease. Brain Pathol 2011; 21: 419-427.
27. Fronczek R, Overeem S, Lee SY, et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007; 130: 1577-1585.
28. Thannickal TC, Lai YY, Siegel JM,. Hypocretin (orexin) and melanin concentrating hormone loss and the symptoms of Parkinson's disease. Brain 2008; 131: e87.
29. Thannickal TC, Lai YY, Siegel JM,. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007; 130: 1586-1595.
30. Shan L, Bossers K, Luchetti S, et al. Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem study. Neurobiol Aging 2012; 33: 1488.e1-1488.e13.
31. Shan L, Liu CQ, Balesar R, et al. Neuronal histamine production remains unaltered in Parkinson's disease despite the accumulation of Lewy bodies and Lewy neurites in the tuberomamillary nucleus. Neurobiol Aging 2012; 33: 1343-1344.
32. Honda Y, Doi Y, Juji T, et al. Narcolepsy and HLA: positive DR2 as a prerequisite for the development of narcolepsy. Folia Psychiatr Neurol Jpn 1984; 38: 360.
33. Mignot E, Thorsby E,. Narcolepsy and the HLA system. N Engl J Med 2001; 344: 692.
34. Thannickal TC, Siegel JM, Moore RY,. Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol 2003; 13: 340-351.
35. Dauvilliers Y, Montplaisir J, Cochen V, et al. Post-H1N1 narcolepsy-cataplexy. Sleep 2010; 33: 1428-1430.
36. Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in china. Ann Neurol 2011; 70: 410-417.
37. Aran A, Lin L, Nevsimalova S, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009; 32: 979-983.
38. Sundvik M, Kudo H, Toivonen P, et al. The histaminergic system regulates wakefulness and orexin/hypocretin neuron development via histamine receptor H1 in zebrafish. FASEB J 2011; 25: 4338-4347.
39. Ishizuka T, Murotani T, Yamatodani A,. Modanifil activates the histaminergic system through the orexinergic neurons. Neurosci Lett 2010; 483: 193-196.
40. Torrealba F, Yanagisawa M, Saper CB,. Colocalization of orexin a and glutamate immunoreactivity in axon terminals in the tuberomammillary nucleus in rats. Neuroscience 2003; 119: 1033-1044.
41. Yamanaka A, Tsujino N, Funahashi H, et al. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun 2002; 290: 1237-1245.
42. Eriksson KS, Sergeeva O, Brown RE, et al. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci 2001; 21: 9273-9279.
43. Sundvik M, Kudo H, Toivonen P, et al. The histaminergic system regulates wakefulness and orexin/hypocretin neuron development via histamine receptor H1 in zebrafish. FASEB J 2011; 25: 4338-4347.
44. Spitzer NC,. Activity-dependent neurotransmitter respecification. Nat Rev Neurosci 2012; 13: 94-106.
45. Lee DA, Blackshaw S,. Functional implications of hypothalamic neurogenesis in the adult mammalian brain. Int J Dev Neurosci 2012; 30: 615-621.
46. Dahlstrom A, Fuxe K,. Localization of monoamines in the lower brain stem. Experientia 1964; 20: 398-399.
47. Kessler BA, Stanley EM, Frederick-Duus D, et al. Age-related loss of orexin/hypocretin neurons. Neuroscience 2011; 178: 82-88.
48. Muschamp JW, Dominguez JM, Sato SM, et al. A role for hypocretin (orexin) in male sexual behavior. J Neurosci 2007; 27: 2837-2845.